VENLO, Netherlands, January 31, 2018 /PRNewswire/ --
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2017, delivering on goals for adjusted net sales and adjusted earnings per share while driving the global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
For the full press release click here
John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29 11711 and +1-240-686-2222 John.firstname.lastname@example.org
Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Sarah.email@example.com
Dr. Thomas Theuringer Senior Director Public Relations and Digital Communications +49-2103-29-11826 and +1-240-686-7425 Thomas.firstname.lastname@example.org
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...View All